The recently approved weight loss medication, Wegovy® (semaglutide), will be in short supply in the first half of 2022 due to manufacturing issues.
Novo Nordisk stated that a contract manufacturer who fills the single-dose prefilled syringe pens has stopped deliveries following issues with Good Manufacturing Practices. The Company says they expect to meet demand in the second half of 2022 and that priority for the first half of the year will go to patients who have already initiated treatment.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30kg/m2 or greater (obesity); or 27kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).
The Food and Drug Administration (FDA) granted approval for the treatment in June 2021 based on results from 3 separate clinical trials that included over 3000 patients.
Wegovy is supplied as prefilled, single-dose pens that deliver doses of 0.25mg, 0.5mg, 1mg, 1.7mg, or 2.4mg. Treatment is administered subcutaneously once weekly by the patient following training on proper technique.
Novo Nordisk announces supply challenges for Wegovy® in the US. News release. Accessed December 20, 2021. https://www.globenewswire.com/news-release/2021/12/17/2354634/0/en/Novo-Nordisk-announces-supply-challenges-for-Wegovy-in-the-US.html.